Fluorocarbon nanoparticles as multifunctional drug delivery vehicles

Journal of Drug Targeting

Volumn 14, Issue 10, 2006, Pages 663-669

  Yu, Y Bruce ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Biomedicine; Drug delivery vehicles; Fluorocarbon nanoparticles; MR imaging; Radiopharmaceuticals

Indexed keywords

15 CROWN 5 DERIVATIVE; 2NITROIMIDAZOLE DERIVATIVE; FLUORINE; FLUOROCARBON; FLUOROSOL D; FS 069; GADOLINIUM; HEXAFLUOROBENZENE; IBRITUMOMAB TIUXETAN; INDIUM 111; NICOTINAMIDE; OCTREOTHER; ORGANOFLUORINE DERIVATIVE; OXYGEN; PACLITAXEL; PERFLUORO 15 CROWN 5 DERIVATIVE; PERFLUOROTRIBUTYLAMINE; RADIOISOTOPE; SURFACTANT; TOSITUMOMAB I 131; YTTRIUM 86; YTTRIUM 89; YTTRIUM 90;

ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG FORMULATION; ENCAPSULATION; HUMAN; MICROEMULSION; NANOPARTICLE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT PLANNING;

CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FLUOROCARBONS; HUMANS; NANOPARTICLES; VEHICLES;

EID: 33845534732     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600957887     Document Type: Article

References (70)

1. Ahrens, ET and Flores, R and Xu, H and Morel, PA. (2005) In vivo imaging platform for tracking immunotherapeutic cells Nat Biotech, 23(8), pp. 983-987.
2. Al-Hallaq, HA and Zamora, M and Fish, BL and Farrell, A and Moulder, JE and Karczmar, GS. (2000) MRI measurements correctly predict the relative effects of tumor oxygenation agents on hypoxic fraction in rodent BA1112 tumors Int J Radiat Oncol Biol Phys, 47, pp. 481-488.
3. 3-targeted nanoparticles Magn Reson Med, 44, pp. 433-439.
4. 19F NMR NMR Biomed, 5, pp. 65-68.
5. Boerman, OC and van Schaijk, FG and Oyen, WJG and Corstens, FHM. (2003) Pretargeted radioimmunotherapy of cancer: Progress step by step J Nucl Med, 44, pp. 400-411.
6. 19F MRI: A comparative animal study Nucl Med Biol, 23, pp. 897-906.
7. 19 F-labeled radiosensitizer 3-aminobenzamide: Assessment by 19F MR imaging Magn Reson Imag, 23, pp. 967-976.
8. 90Y-SMT 487 in patients with neuroendocrine tumors J Nucl Med, 44, pp. 1556-1560.
9. Canera, L and Kinuya, S and Garmestani, K and Brechbiel, MW and Wu, C and Pai, LH and McMurry, TJ and Gansow, OA and Pastan, I and Paik, CH and Carrasquillo, JA. (1994) Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA) Eur J Nucl Med, 21, pp. 640-646.
10. Carrasquillo, JA and White, JD and Paik, CH and Raubitschek, A and Le, N and Rotman, M and Brechbiel, MW and Gansow, OA and Top, LE and Perentesis, P and Reynolds, JC and Nelson, DL and Waldman, TA. (1999) Similarities and differences in 111In and 90Y-labeled antiTac monoclonal antibody distribution J Nucl Med, 40, pp. 268-276.
11. Chandler, D. (1978) Structures of molecular liquids Annu Rev Phys Chem, 29, pp. 441-471.
12. Curran, D and Lee, Z. (2001) Fluorous techniques for the synthesis and separation of organic molecules Green Chem, pp. G3-G7.
13. Fan, X and River, JN and Zamora, M and Al-Hallaq, HA and Karczmar, GS. (2002) Effect of carbogen on tumor oxygenation: Combined fluorine-19 and proton MRI measurements Int J Radiat Oncol Biol Phys, 54, pp. 1202-1209.
14. Flacke, S and Fischer, S and Scott, MJ and Fuhrhop, RJ and Allen, JS and McLean, M and Winter, P and Sicard, GA and Gaffney, PJ and Wickline, SA and Lanza, GM. (2001) Novel MRI contrast agent for molecular imaging of fibrin Circulation, 104, pp. 1280-1285.
15. Fyles, AW and Milosevic, M and Wong, R and Kavanagh, M-C and Pintilie, M and Sun, A and Chapman, W and Levin, W and Manchul, L and Keane, TJ and Hill, RP. (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer Radiother Oncol, 48, pp. 149-156.
16. Goldenberg, DM. (2002) Targeted therapy of cancer with radiolabeled antibodies J Nucl Med, 43, pp. 693-713.
17. Hamblett, KJ and Kegley, BB and Hamlin, DK and Chyan, MK and Hyre, DE and Press, OW and Wilbur, DS and Stayton, PS. (2002) A streptavidin-biotin system that minimizes blocking by endogenous biotin Bioconjug Chem, 13, pp. 588-598.
18. Huang, MQ and Basse, PH and Yang, Q and Horner, JA and Hichens, TK and Ho, C. (2004) MRI detection of tumor in mouse lung using partial liquid ventilation with a perfluorocarbon-in-water emulsion Magn Reson Imag, 22, pp. 645-652.
19. 19F NMR spectroscopy of hexafluorobenzene Int J Radiat Oncol Biol Phys, 41, pp. 161-171.
20. 19F magnetic resonance imaging of perfluorooctanoic acid encapsulated in liposome for biodistribution measurement Magn Reson Imag, 22, pp. 855-860.
21. Klibanov, AL. (2005) Ligand-carrying gas-filled microbubbles: Ultrasound contrast agents for targeted molecular imaging Bioconjug Chem, 16, pp. 9-17.
22. Knox, SJ and Goris, ML and Tempero, M and Weiden, PL and Gentner, L and Breitz, H and Adams, GP and Axworthy, D and Gaffigan, S and Bryan, K and Fisher, DR and Colcher, D and Horak, ID and Weiner, LM. (2000) Phase II trial of yttrium-90-DOTA pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer Clin Cancer Res, 6, pp. 406-414.
23. Koch, CJ and Oprysko, PR and Shuman, AL and Jenkins, WT and Brandt, G and Evans, SM. (2002) Radiosensitization of hypoxic tumor cells by dodecafluoropentane: A gas-phase perfluorocarbon emulsion Cancer Res, 62, pp. 3626-3629.
24. Koziara, JM and Lockman, PR and Allen, DD and Mumper, RJ. (2003) In situ blood-brain barrier transport of nanoparticles Pharm Res, 20, pp. 1772-1778.
25. Kreuter, J. (2001) Nanoparticle systems for brain delivery of drugs Adv Drug Del Rev, 47, pp. 65-81.
26. Lanza, GM and Wickline, SA. (2001) Targeted ultrasonic contrast agents for molecular imaging and therapy Prog Cardiovasc Dis, 44, pp. 13-31.
27. Lanza, GM and Wallace, KD and Scott, MJ and Cacheris, WP and Abendschein, DR and Christy, DH and Sharkey, AM and Miller, JG and Gaffney, PJ and Wickline, SA. (1996) A novel site-targeted ultraosonic contrast agent with broad biomedical application Circulation, 94, pp. 3334-3340.
28. Lanza, GM and Abendschein, DR and Hall, CS and Marsh, JN and Scott, MJ and Scherrer, DE and Wickline, SA. (2000) Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound Invest Radiol, 35, pp. 227-234.
29. Lanza, GM and Yu, X and Winter, PM and Abendschein, DR and Karukstis, KK and Scott, MJ and Chinen, LK and Fuhrhop, RW and Scherrer, DE and Wickline, SA. (2002) Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent Circulation, 106, pp. 2842-2847.
30. 111In-labeled DOTA-biomolecule conjugates Bioconjug Chem, 13, pp. 902-913.
31. 19F NMR imaging of liver, tumor, and abscess in rats Invest Radiol, 20, pp. 141-145.
32. 111In radiolabels J Nucl Med, 42, pp. 1281-1287.
33. 19F MRI study in tumor-bearing mice Magn Reson Imag, 7, pp. 475-485.
34. 19F NMR spectroscopy of perfluorocarbon Magn Reson Med, 29, pp. 296-302.
35. Mason, RP and Hunjan, S and Le, D and Constaninescu, A and Barker, BR and Wong, PS and Peschke, P and Hahn, EW and Antich, PP. (1998) Regional tumor oxygen tension: Fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics Int J Radiat Oncol Biol Phys, 42, pp. 747-750.
36. 19F magnetic resonance imaging of perfluorocarbons Curr Sci, 76, pp. 753-761.
37. Meyer, KL and Carvlin, MJ and Mukherji, B and Sloviter, HA and Joseph, PM. (1992) Fluorinated blood substitute retention in the rat measured by fluorine-19 magnetic resonance imaging Invest Radiol, 27, pp. 620-627.
38. Mishima, H and Kobayashi, T and Shimizu, M and Tamaki, Y and Baba, M and Shimano, T and Itoh, S and Yamazaki, M and Iriguchi, N and Takahashi, M and Takesada, M. (1991) In vivo F-19 shift imaging with FTPA and antibody-coupled FMIQ J Magn Reson Imag, 1, pp. 705-709.
39. Morawski, AM and Winter, PM and Crowder, KC and Caruthers, SD and Fuhrhop, RW and Scott, MJ and Robertson, JD and Abendschein, DR and Lanza, GM and Wickline, SA. (2004a) Targeted nanoparticles for quantitative imaging of spare molecular epitopes with MRI Magn Reson Med, 51, pp. 480-486.
40. 19F nanoparticles Magn Reson Med, 52, pp. 1255-1262.
41. Niiler, E. (2002) Setbacks for blood substitute companies Nat Biotech, 209, pp. 62-963.
42. Nordsmark, M and Overgaard, J. (2000) A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy Radiother Oncol, 57, pp. 39-43.
43. 2 measurements by EPR oximetry Radiat Res, 150, pp. 549-556.
44. 2 measured by EPR oximetry in human tumor xenografts Radiat Res, 155, pp. 466-473.
45. Otte, A and Herrmann, R and Heppeler, A and Behe, M and Jermann, E and Powell, P and Maecke, HR and Muller, J. (1999) Yttrium-90 DOTATOC: First clinical results Eur J Nucl Med, 26, pp. 1439-1447.
46. Paganelli, G and Zoboli, S and Cremonesi, M and Bodei, L and Ferrari, M and Grana, C and Bartolomei, M and Orsi, F and de Cicco, C and Macke, HR and Chinol, M and de Braud, D. (2001) Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide Eur J Nucl Med, 28, pp. 426-434.
47. Parhaml, P and Fung, BM. (1983) Fluorine-19 relaxation study of perfluoro chemicals as oxygen carriers J Phys Chem, 87, pp. 1928-1931.
48. Postel, M and Riess, JG and Weers, JG. (1994) Fluorocarbon emulsions - the stability issue Artif Cells Blood Substit Immobil Biotechnol, 22, pp. 991-1005.
49. 19F magnetic resonance imaging Invest Radiol, 23, pp. 361-364.
50. Riess, JG. (2001) Oxygen carriers ("blood substitutes") - raison d'etre, chemistry and some physiology Chem Rev, 101, pp. 2797-2919.
51. Riess, JG. (2005) Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery Artif Cells Blood Substit Biotechnol, 33, pp. 47-63.
52. 19F nuclear magnetic resonance methodologies for the assessment of tumor hypoxia Phil Trans R Soc Lond B, 359, pp. 987-996.
53. Rockwell, S. (1985) Use of a perfluorochemical emulsion to improve oxygenation in a solid tumor Int J Radiat Oncol Biol Phys, 11, pp. 97-103.
54. Rose, C and Lustig, R and McIntosh, N and Teicher, B. (1986) A clinical trial of Fluosol DA 20% in advanced cell carcinoma of the head and neck Int J Radiat Oncol Biol Phys, 12, pp. 1325-1327.
55. Schlemmer, HP and Becker, M and Bachert, P and Dietz, A and Rudat, V and Vanselow, B and Wollensack, P and Zuna, I and Knopp, MV and Weidauer, H and Wannenmacher, M and van Kaick, G. (1999) Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy Cancer Res, 59, pp. 2363-2369.
56. 3-targeted paramagnetic nanoparticles Magn Reson Med, 53, pp. 621-627.
57. 19F emulsion Magn Reson Med, 5, pp. 290-295.
58. 19F NMR probes of oxygen tension and temperature J Magn Reson Ser B, 106, pp. 131-141.
59. Tarara, TE and Malinoff, SH and Pelura, TJ. (1994) Oxidative assessment of phospholipid-stabilized perfluorocarbon-based blood substitutes Artif Cells Blood Substit Immobil Biotechnol, 22, pp. 1287-1293.
60. Teicher, BA and Rose, CM. (1984a) Perfluorochemical emulsions can increase tumor radiosensitivity Science, 223, pp. 934-936.
61. Teicher, BA and Rose, CM. (1984b) Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice Cancer Res, 44, pp. 4285-4288.
62. Thomas, C and Riess, J and Guichard, M. (1991) Influence of the 100% w/v perfluorooctyl bromide (PFOB) emulsion dose on tumor radiosensitivity Int J Radiat Biol, 59(2), pp. 433-445.
63. Thomas, CD and Prade, M and Guichard, M. (1995) Tumour oxygenation, radiosensitivity, and necrosis before and/or adfter nicotiamide, carbogen and perflubron emulsion administration Int J Radiat Biol, 67(5), pp. 597-605.
64. 19F-MR relaxometry Int J Radiat Oncol Biol Phys, 44, pp. 649-658.
65. van der Sanden, BPJ and Heerschap, A and Hoofd, L and Simonetti, AW and Nicolay, K and van der Toorn, A and Colier, WNJM and van der Kodel, AJ. (1999b) Effect of carbogen breathing on ths physiological profile of human glioma xenografts Magn Reson Imag, 42, pp. 490-499.
66. Wahl, RL. (2005) Tositumomab and 131I therapy in non-Hodgkin's lymphoma J Nucl Med, 46(Suppl. 1), pp. 128S-140S.
67. 3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging Cancer Res, 63, pp. 5838-5843.
68. Winter, PM and Caruthers, SD and Yu, X and Song, S-K and Chen, J and Miller, B and Bulte, JWM and Robertson, JD and Gaffney, PJ and Wickline, SM and Lanza, GM. (2003b) Improved molecular imaging contrast agent for detection of human thrombus Magn Reson Med, 50, pp. 411-416.
69. Zhao, D and Constantinescu, A and Jiang, L and Hahn, EW and Mason, RP. (2001) Prognostic radiology: Quantitative assessment of tumor oxygen dynamics by MRI Am J Clin Oncol, 24, pp. 462-466.
70. Zhao, D and Jiang, L and Mason, RP. (2004) Measuring changes in tumor oxygenation Methods Enzymol, 386, pp. 378-418.